🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records — a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials with a site in France

884 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT)
2023-510075-63-00Patients with ventilator-associated tracheobronchitis
Centre Hospitalier Regional Universitaire De Tours
Bacterial Infections and Mycoses
France
12/01/2026
Phase III
A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors
2025-521043-20-00Neuroendocrine tumors
Exelixis Inc.
Neoplasms
France, Poland, Netherlands, Belgium, Germany, Spain, Italy, Austria
09/01/2026
Phase II
Efficacy and safety of Remimazolam compared to Ketamine and Propofol in Rapid Sequence Induction. A monocentric pilot randomised-controlled study
2025-521602-18-00Rapid Sequence Induction in operating room
Centre Hospitalier Universitaire De Nantes
Anesthesia and Analgesia
France
06/01/2026
Phase IV
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer
2025-521696-31-00HR+, HER2- breast cancer at high risk of recurrence
Centre Hospitalier Universitaire De Poitiers
Neoplasms
France
06/01/2026
Phase III
A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)
2025-523690-41-00Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca AB
Respiratory Tract Diseases
France
24/12/2025
Phase III
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
2023-508784-68-00metastatic uveal melanoma
Replimune Inc.
Neoplasms
Germany, Italy, France, Spain, Poland
23/12/2025
Phase I/II
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.
2025-522139-33-00Advanced or metastatic solid tumours
Ipsen Pharma
Neoplasms
France, Spain
23/12/2025
Phase II
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
2025-520675-86-00Unresectable or Metastatic Hepatocellular Carcinoma and Com…
CatalYm GmbH
Neoplasms
Germany, France, Italy, Spain
23/12/2025
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease
2025-522683-32-00Early-Stage Parkinson’s Disease (PD)
F. Hoffmann-La Roche AG
Nervous System Diseases
France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy
23/12/2025
Phase II
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa
2025-522333-61-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece
22/12/2025
Phase IV
TRAMORNOT: Tramadol versus morphine in postoperative analgesia after laparoscopic abdominal surgery: a randomized controlled trial
2025-523327-21-00Postoperative pain following scheduled major laparoscopic a…
Centre Hospitalier Universitaire Amiens Picardie
Anesthesia and Analgesia
France
22/12/2025
Phase III
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
2025-521117-88-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
France, Denmark, Germany, Spain, Italy, Netherlands
22/12/2025
Phase III
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
2024-515765-34-00English First-line extensive-stage small-cell lung cancer (…
BioNTech SE
Neoplasms
Poland, Spain, France, Italy, Germany, Romania, Netherlands
22/12/2025
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase III
C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase II
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.
2025-522309-40-00Non-segmental vitiligo
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
Poland, Italy, Spain, France
19/12/2025
Phase I
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.
2025-523587-20-00Not applicable for phase I study
Gruenenthal GmbH
Not possible to specify
France
19/12/2025
Phase III
IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
2025-522400-24-00Metastatic urothelial cancer
Bristol-Myers Squibb Services Unlimited Company
Female Urogenital Diseases and Pregnancy Complications
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase III
A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
2025-522361-30-00Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G va…
Khondrion B.V.
Nervous System Diseases
Italy, Germany, France, Netherlands, Denmark
19/12/2025
Phase III
A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)
2025-522996-27-00recurrent and/or metastatic squamous cell carcinoma of the …
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France, Spain, Belgium
18/12/2025
Phase I/II
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
2025-521873-15-00Metastatic hormone-sensitive prostate cancer
Novartis Pharma AG
Neoplasms
Hungary, Spain, Italy, Germany, France
18/12/2025
Phase IV
Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial
2025-523207-29-00colorectal cancer laparoscopic surgery
Centre Hospitalier Universitaire Amiens Picardie
Not possible to specify
France
17/12/2025
Phase III
C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
2025-522093-36-00Cancer cachexia
Pfizer Inc.
Nutritional and Metabolic Diseases
Slovakia, Italy, Belgium, Germany, Spain, France, Bulgaria, Poland
16/12/2025
Phase III
Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung’s disease
2025-523094-42-00Hirschsprung's disease
Assistance Publique Hopitaux De Marseille
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
16/12/2025
Phase I/II
An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
2025-522184-15-00Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen Pharma
Neoplasms
Spain, France
16/12/2025
Phase II
Is [18F]-DPA-714 PET a good marker of neuroinflammation in autoimmune encephalitis? (EAI-714)
2025-522768-33-00autoimmune encephalitis
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
15/12/2025
Phase III
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease
2025-521113-13-00Early Parkinson’s Disease
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase III
Intermediate versus standard dose enoxaparin to prevent venous thromboembolism in severe trauma patients: a multicenter double blind randomised controlled trial (HEPTRAUMA)
2025-522832-16-00Severe trauma
Centre Hospitalier Universitaire Grenoble Alpes
Hemic and Lymphatic Diseases
France
11/12/2025
Phase III
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
2024-519444-33-00HER2-expressing endometrial cancer (IHC 3+/2+)
Daiichi Sankyo Inc.
Neoplasms
Germany, Poland, France, Greece, Spain, Portugal, Italy
11/12/2025
Phase II
A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
2024-519393-39-00Angelman Syndrome
Ultragenyx Pharmaceutical Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Portugal, Italy, France
11/12/2025
Phase III
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
2025-522151-26-00Advanced or Metastatic Non-Small-Cell Lung Cancer With Epid…
Arrivent Biopharma Inc.
Neoplasms
Greece, France, Spain, Italy
10/12/2025
Phase III
AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00Philadelphia Chromosome Positive or ABL-class Philadelphia …
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase II
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)
2024-519788-16-00Adult patients with histologically/cytologically confirmed …
Institut Gustave Roussy
Neoplasms
France
09/12/2025
Phase II
SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre, single-arm, open-label phase II trial
2023-509713-37-00Patient with severe eye chemical burns
Hopital Fondation Adolphe De Rothschild
Eye Diseases
France
09/12/2025
Phase III
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension
2024-519578-38-00Classic congenital adrenal hyperplasia
Crinetics Pharmaceuticals Inc.
Hormonal diseases
Italy, Germany, France, Belgium, Netherlands, Poland
09/12/2025
Phase III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia
09/12/2025
Phase III
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
2023-509392-17-00Relapsed Acute Lymphoblastic Leukemia (ALL)
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Slovenia
09/12/2025
Phase II
An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.
2025-521852-45-00Cutaneous T-Cell Lymphoma
Prescient Therapeutics Limited
Neoplasms
Italy, France
08/12/2025
Phase III
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
2024-512804-20-00Metastatic Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, France, Italy, Netherlands, Spain
08/12/2025
Phase II
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
2024-518231-11-00Immune thrombocytopenia (ITP) Warm autoimmune hemolytic an…
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase II
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
2024-516471-33-00Chronic kidney disease, Alport Syndrome
Bayer AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, Poland, Czechia, Germany, Portugal, France
05/12/2025
Phase II
A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis
2024-517980-22-00Multiple Sclerosis (MS)
F. Hoffmann-La Roche AG
Immune System Diseases
Poland, Italy, France, Spain, Germany
05/12/2025
Phase III
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
2024-512486-14-00Short Bowel Syndrome
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase II
A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
2025-522074-37-00Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertensi…
Allrock Bio Inc.
Cardiovascular Diseases
Spain, Italy, Poland, France, Latvia, Germany
04/12/2025
Phase I
First-in-Human trial of DS9051b in participants with advanced solid tumors
2025-521886-28-00Advanced or Metastatic Adrenocortical Carcinoma (ACC), Meta…
Daiichi Sankyo Inc.
Neoplasms
France
03/12/2025
Phase III
Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).
2023-505469-95-00Primary Sclerosing Cholangitis
Assistance Publique Hopitaux De Paris
Nutritional and Metabolic Diseases
France
02/12/2025
Phase IV
Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2
2025-521217-46-00Adults seeking active immunisation against the seasonal inf…
Centre Hospitalier Universitaire De Saint Etienne
Virus Diseases
France
02/12/2025
Phase II
A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study
2025-523339-20-00Leber Hereditary Optic Neuropathy due to mutations in the m…
Gensight Biologics
Eye Diseases
France
02/12/2025
Phase III
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
2024-512298-28-00Neovascular age-related macular degeneration
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase III
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
2024-519579-24-00Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Hormonal diseases
Sweden, Austria, Poland, Netherlands, Italy, France, Germany
02/12/2025
Phase II
C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
2025-521155-23-00Pulmonary Arterial Hypertension
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
2024-520337-80-00Palmoplantar Pustulosis
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
2025-521382-27-00Moderately to Severely Active Crohn's Disease
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
2025-521381-10-00Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
Digestive System Diseases
Netherlands, Romania, Italy, Spain, Sweden, Czechia, Greece, Hungary, France, Portugal, Belgium, Germany, Poland
01/12/2025
Phase I/II
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Italy, Germany, Poland, France, Denmark, Spain
01/12/2025
Phase III
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
2025-521970-33-00​​Pulmonary Arterial Hypertension (PAH)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2024-520097-36-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase II
A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
2025-522146-40-00Late-onset Pompe disease.
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase II
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Inc.
Genetic Phenomena
France, Germany, Italy, Belgium, Spain, Netherlands
28/11/2025
Phase I
A study to find a suitable dose of ASP5834 in adults with solid tumors
2025-522082-29-00Locally advanced (unresectable) or metastatic solid tumor m…
Astellas Pharma Inc.
Neoplasms
Spain, France
28/11/2025
Phase III
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
2025-522598-12-00Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase III
Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement: a randomized, placebo-controlled, double-blinded multicenter superiority study
2024-519620-24-01ANCA-associated vasculitis
Centre Hospitalier Universitaire De Toulouse
Immune System Diseases
France
27/11/2025
Phase II
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2025-520730-28-00Common EGFR-Mutated Locally Advanced or Metastatic Non-Smal…
Janssen Cilag International
Neoplasms
Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France
27/11/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
2024-514500-14-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Germany, Italy, France, Poland, Spain, Hungary, Romania, Greece, Austria, Netherlands, Belgium
27/11/2025
Phase IV
Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK
2024-511595-32-00Acute low back pain
Centre Hospitalier Universitaire De Montpellier
Anesthesia and Analgesia
France
26/11/2025
Phase I/II
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
2025-522510-23-00Hereditary Hemorrhagic Telangiectasia (HHT)
Alnylam Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Germany
26/11/2025
Phase I
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
2023-509729-33-00Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
Institut De Cancerologie De L Ouest
Neoplasms
France
26/11/2025
Phase III
A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials
2025-520775-81-00Short Bowel Syndrome
Zealand Pharma A/S
Digestive System Diseases
Poland, France, Germany, Belgium
26/11/2025
Phase II
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
2025-522054-40-00Previously treated advanced melanoma
Iovance Biotherapeutics Inc.
Skin and Connective Tissue Diseases
France, Italy, Germany, Spain
26/11/2025
Phase I/II
A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor
2025-521128-31-00Locally Advanced or Metastatic Estrogen Receptor-Positive, …
Genentech Inc.
Neoplasms
Spain, Italy, France, Germany
26/11/2025
Phase III
Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
2024-513911-28-00Acute Ischemic Stroke
Diamedica Therapeutics Inc.
Nervous System Diseases
Romania, Hungary, Belgium, Poland, Spain, France
25/11/2025
Phase I
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
2024-518780-36-00Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
Musculoskeletal Diseases
Bulgaria, Romania, France, Germany, Spain, Poland
25/11/2025
Phase III
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
2023-508071-36-00Patients hospitalised in intensive care, diagnosed with sep…
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase II
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00Folliculitis decalvans
Assistance Publique Hopitaux De Paris
Therapeutics
France
24/11/2025
Phase IV
Comparison of morphine and alfentanil in the emergency treatment of severe acute pain in the pre-hospital setting
2025-522817-50-00Severe pain
CHU De Martinique
Population Characteristics
France
24/11/2025
Phase II
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
2025-521371-31-00Sepsis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase III
Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
2024-515023-11-00Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear …
Arcus Biosciences Inc.
Neoplasms
Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary
24/11/2025
Phase III
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.
2024-520418-22-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase II
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
2025-521034-28-00Moderate to Severe Rheumatoid Arthritis (RA)
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase I
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.
2025-521407-52-00Advanced Solid Tumors
Janssen Cilag International
Neoplasms
France
21/11/2025
Phase I/II
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
2025-521672-60-00Metastatic or locally advanced SST2-positive neuroendocrine…
Crinetics Pharmaceuticals Inc.
Neoplasms
Spain, France, Germany, Italy
21/11/2025
Phase III
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00Macular neovascularization secondary to age-related macular…
4d Molecular Therapeutics Inc.
Eye Diseases
Germany, Italy, Hungary, Bulgaria, Lithuania, France, Spain, Latvia, Portugal
21/11/2025
Phase II
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)
2025-520780-40-00Primary Mebranous Nephropathy (PMN)
Alexion Pharmaceuticals Inc.
Immune System Diseases
Spain, France, Italy
20/11/2025
Phase II
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy
Imbria Pharmaceuticals Inc.
Cardiovascular Diseases
Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland
20/11/2025
Phase I/II
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
2025-521828-30-00Advanced Solid Tumors
Pyxis Oncology Inc.
Neoplasms
France, Spain, Poland
19/11/2025
Phase III
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
2025-522860-34-00Small lymphocytic lymphoma (SLL), Chronic lymphocytic leuke…
BeOne Medicines AG
Neoplasms
Sweden, Belgium, Spain, Germany, Austria, Netherlands, Italy, Romania, Poland, France
18/11/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
2025-520927-26-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
France, Belgium, Spain, Poland, Italy, Netherlands, Germany
18/11/2025
Phase II
Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
2025-521706-17-00Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasc…
Alexion Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, France, Italy, Germany, Poland
17/11/2025
Phase II
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
2025-521322-14-00Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1…
French Innovative Leukemia Organization
Hemic and Lymphatic Diseases
France
17/11/2025
Phase II
ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders
2025-522841-23-00Autism Spectrum disorder ASD
Assistance Publique Hopitaux De Paris
Mental Disorders
France
17/11/2025
Phase III
C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial
2025-520979-13-00Patients with HR+ HER2- early breast cancer at intermediate…
Unicancer
Neoplasms
Germany, Spain, Netherlands, France, Italy
17/11/2025
Phase III
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
2024-518777-34-00B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia
17/11/2025
Phase II
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 2B TRIAL TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0217 FOR 24 WEEKS IN ADULTS AND OLDER ADOLESCENTS WITH DOWN SYNDROME
2025-521013-10-00Treatment of behavioural and cognitive impairments in Down …
Aelis Farma
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, France
17/11/2025
Phase III
LEISURE : Lenalidomide vs methotrexate in difficult-to-treat cutaneous lupus erythematosus (LEISURE trial): An assessor-blinded randomized clinical trial
2024-520089-70-00Cutaneous lupus erythematosus
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
France
14/11/2025
Phase II
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
2024-517711-70-01Narcolepsy without Cataplexy (NT2)
Takeda Development Center Americas Inc.
Nervous System Diseases
Spain, Italy, France
14/11/2025
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials
2025-520771-59-00Atopic Dermatitis
F. Hoffmann-La Roche AG
Skin and Connective Tissue Diseases
Italy, Poland, Germany, Spain, France
13/11/2025
Phase II
A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206)
2024-516551-41-00Patients with HER2-expressing solid tumors
Jazz Pharmaceuticals Ireland Limited
Neoplasms
Spain, France, Italy
13/11/2025
Phase II
A DOSE-DETERMINATION STUDY OF SUGAMMADEX AS A ROCURONIUM DECURARIZATION AGENT IN CHILDREN UNDER 2 YEARS OF AGE
2025-521946-82-00Non-urgent non-cardiac surgical procedure or relative emerg…
Centre Hospitalier Universitaire De Caen Normandie
Anesthesia and Analgesia
France
12/11/2025
Rows per page Showing 601–700 of 884
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france?page=7

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 884 of those trials with a site in France.

How many recently authorised EU trials have a site in France?

884 of the 2,500 most recently authorised trials in this register list a site in France; 408 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.